The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report
dc.contributor.author | Neogi, Tuhina | en_US |
dc.contributor.author | Aletaha, Daniel | en_US |
dc.contributor.author | Silman, Alan J. | en_US |
dc.contributor.author | Naden, Raymond L. | en_US |
dc.contributor.author | Felson, David T. | en_US |
dc.contributor.author | Aggarwal, Rohit | en_US |
dc.contributor.author | Bingham, Clifton O. | en_US |
dc.contributor.author | Birnbaum, Neal S. | en_US |
dc.contributor.author | Burmester, Gerd R. | en_US |
dc.contributor.author | Bykerk, Vivian P. | en_US |
dc.contributor.author | Cohen, Marc D. | en_US |
dc.contributor.author | Combe, Bernard | en_US |
dc.contributor.author | Costenbader, Karen H. | en_US |
dc.contributor.author | Dougados, Maxime | en_US |
dc.contributor.author | Emery, Paul | en_US |
dc.contributor.author | Ferraccioli, Gianfranco | en_US |
dc.contributor.author | Hazes, Johanna M. W. | en_US |
dc.contributor.author | Hobbs, Kathryn | en_US |
dc.contributor.author | Huizinga, Tom W. J. | en_US |
dc.contributor.author | Kavanaugh, Arthur F. | en_US |
dc.contributor.author | Kay, Jonathan | en_US |
dc.contributor.author | Khanna, Dinesh | en_US |
dc.contributor.author | Kvien, Tore K. | en_US |
dc.contributor.author | Laing, Timothy J. | en_US |
dc.contributor.author | Liao, Katherine | en_US |
dc.contributor.author | Mease, Philip J. | en_US |
dc.contributor.author | Ménard, Henri A. | en_US |
dc.contributor.author | Moreland, Larry W. | en_US |
dc.contributor.author | Nair, Raj | en_US |
dc.contributor.author | Pincus, Theodore | en_US |
dc.contributor.author | Ringold, Sarah | en_US |
dc.contributor.author | Smolen, Josef S. | en_US |
dc.contributor.author | Stanislawska-Biernat, Ewa | en_US |
dc.contributor.author | Symmons, Deborah | en_US |
dc.contributor.author | Tak, Paul P. | en_US |
dc.contributor.author | Upchurch, Katherine S. | en_US |
dc.contributor.author | Vencovský, Jirí | en_US |
dc.contributor.author | Wolfe, Frederick | en_US |
dc.contributor.author | Hawker, Gillian | en_US |
dc.date.accessioned | 2010-10-06T14:54:06Z | |
dc.date.available | 2011-03-01T16:26:41Z | en_US |
dc.date.issued | 2010-09 | en_US |
dc.identifier.citation | Neogi, Tuhina; Aletaha, Daniel; Silman, Alan J.; Naden, Raymond L.; Felson, David T.; Aggarwal, Rohit; Bingham, Clifton O.; Birnbaum, Neal S.; Burmester, Gerd R.; Bykerk, Vivian P.; Cohen, Marc D.; Combe, Bernard; Costenbader, Karen H.; Dougados, Maxime; Emery, Paul; Ferraccioli, Gianfranco; Hazes, Johanna M. W.; Hobbs, Kathryn; Huizinga, Tom W. J.; Kavanaugh, Arthur; Kay, Jonathan; Khanna, Dinesh; Kvien, Tore K.; Laing, Timothy; Liao, Katherine; Mease, Philip; MÉnard, Henri A.; Moreland, Larry W.; Nair, Raj; Pincus, Theodore; Ringold, Sarah; Smolen, Josef S.; Stanislawska-Biernat, Ewa; Symmons, Deborah; Tak, Paul P.; Upchurch, Katherine S.; VencovskÝ, JirÍ; Wolfe, Frederick; Hawker, Gillian (2010). "The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report." Arthritis & Rheumatism 62(9): 2582-2591. <http://hdl.handle.net/2027.42/78048> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/78048 | |
dc.description.abstract | Objective The American College of Rheumatology and the European League Against Rheumatism have developed new classification criteria for rheumatoid arthritis (RA). The aim of Phase 2 of the development process was to achieve expert consensus on the clinical and laboratory variables that should contribute to the final criteria set. Methods Twenty-four expert RA clinicians (12 from Europe and 12 from North America) participated in Phase 2. A consensus-based decision analysis approach was used to identify factors (and their relative weights) that influence the probability of “developing RA,” complemented by data from the Phase 1 study. Patient case scenarios were used to identify and reach consensus on factors important in determining the probability of RA development. Decision analytic software was used to derive the relative weights for each of the factors and their categories, using choice-based conjoint analysis. Results The expert panel agreed that the new classification criteria should be applied to individuals with undifferentiated inflammatory arthritis in whom at least 1 joint is deemed by an expert assessor to be swollen, indicating definite synovitis. In this clinical setting, they identified 4 additional criteria as being important: number of joints involved and site of involvement, serologic abnormality, acute-phase response, and duration of symptoms in the involved joints. These criteria were consistent with those identified in the Phase 1 data-driven approach. Conclusion The consensus-based, decision analysis approach used in Phase 2 complemented the Phase 1 efforts. The 4 criteria and their relative weights form the basis of the final criteria set. | en_US |
dc.format.extent | 332547 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationother | Boston University School of Medicine, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Medical University of Vienna, Vienna, Austria ; Dr. Aletaha has received consulting fees, speaking fees, and/or honoraria from Abbott, Bristol-Myers Squibb, UCB, Schering-Plough, Wyeth, and Roche (less than $10,000 each). | en_US |
dc.contributor.affiliationother | Arthritis Research UK, Chesterfield, UK | en_US |
dc.contributor.affiliationother | Ministry of Health, Auckland, New Zealand ; Dr. Naden has received consulting fees from the American College of Rheumatology in regard to the methodology of developing weighted scoring systems (more than $10,000). | en_US |
dc.contributor.affiliationother | Boston University School of Medicine, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | University of Pittsburgh, Pittsburgh, Pennsylvania | en_US |
dc.contributor.affiliationother | Johns Hopkins University, Baltimore, Maryland ; Dr. Bingham has received consulting fees, speaking fees, and/or honoraria from UCB, Roche, Genentech, Celgene, and Merck Serono (less than $10,000 each); he has received research and/or educational grant support from Bristol-Myers Squibb, Genentech, UCB, Centocor, Abbott, and Amgen. | en_US |
dc.contributor.affiliationother | California Pacific Medical Center and University of California, San Francisco ; Dr. Birnbaum has received consulting fees, speaking fees, and/or honoraria from Amgen, Pfizer, Centocor, Abbott, and UCB (less than $10,000 each). | en_US |
dc.contributor.affiliationother | CharitÉ Hospital–University Medicine Berlin, Free University and Humboldt University, Berlin, Germany ; Dr. Burmester has received consulting fees, speaking fees, and/or honoraria from Abbott, Bristol-Myers Squibb, Pfizer, UCB, and Roche (less than $10,000 each). | en_US |
dc.contributor.affiliationother | Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada ; Dr. Bykerk has received consulting fees, speaking fees, and/or honoraria from Amgen, Wyeth, Abbott, Schering-Plough, Roche, Bristol-Myers Squibb, and UCB (less than $10,000 each); her spouse is employed by Genzyme and owns stock in the company. | en_US |
dc.contributor.affiliationother | National Jewish Medical and Research Center, Denver, Colorado ; Dr. Cohen has received consulting fees, speaking fees, and/or honoraria from UCB, Genentech, Bristol-Myers Squibb, and Human Genome Sciences (less than $10,000 each). | en_US |
dc.contributor.affiliationother | Lapeyronie Hospital and Montpellier I University, Montpellier, France ; Dr. Combe has received consulting fees, speaking fees, and/or honoraria from Abbott, Bristol-Myers Squibb, Pfizer, Roche, Schering-Plough, and Merck, Sharpe, and Dohme (less than $10,000 each). | en_US |
dc.contributor.affiliationother | Brigham and Women's Hospital and Harvard University, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Cochin Hospital, Assistance Publique HÔpitaux de Paris, and Paris-Descartes University, Paris, France | en_US |
dc.contributor.affiliationother | University of Leeds and NIHR Leeds Biomedical Research Unit, Leeds, UK ; Dr. Emery has received consulting fees, speaking fees, and/or honoraria from Pfizer, Abbott, Centocor, UCB, Roche, Bristol-Myers Squibb, and Merck, Sharpe, and Dohme (less than $10,000 each). | en_US |
dc.contributor.affiliationother | School of Medicine, Catholic University of the Sacred Heart, Rome, Italy ; Dr. Ferraccioli holds a patent for T cell receptor clonotype analysis (PCT/IB 2008/053152 NP). | en_US |
dc.contributor.affiliationother | Erasmus Medical Center and University of Rotterdam, Rotterdam, The Netherlands | en_US |
dc.contributor.affiliationother | University of Colorado School of Medicine, Denver | en_US |
dc.contributor.affiliationother | Leiden University Medical Center, Leiden, The Netherlands ; Dr. Huizinga has received consulting fees, speaking fees, and/or honoraria from Schering-Plough, Bristol-Myers Squibb, UCB, Biotest AG, Wyeth/Pfizer, Novartis, Roche, Sanofi-Aventis, Abbott, and Axis-Shield (less than $10,000 each). | en_US |
dc.contributor.affiliationother | University of California, San Diego ; Dr. Kavanaugh has conducted clinical research for Amgen, Abbott, Bristol-Myers Squibb, UCB, Roche, Centocor, Genentech, and Sanofi-Aventis. | en_US |
dc.contributor.affiliationother | UMassMemorial Medical Center and University of Massachusetts Medical School, Worcester ; Dr. Kay has received consulting fees from Array BioPharma, Bristol-Myers Squibb, Celgene, Centocor, Genentech, Roche, UCB, and Sanofi-Aventis (less than $10,000 each). | en_US |
dc.contributor.affiliationother | David Geffen School of Medicine at University of California, Los Angeles ; Dr. Khanna has received consulting fees, speaking fees, and/or honoraria from UCB and Abbott (less than $10,000 each). | en_US |
dc.contributor.affiliationother | Diakonhjemmet Hospital, Oslo, Norway | en_US |
dc.contributor.affiliationother | Brigham and Women's Hospital and Harvard University, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Swedish Medical Center and University of Washington, Seattle ; Dr. Mease has received consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, Roche, Genentech, UCB, Pfizer, Novartis, and Eli Lilly (less than $10,000 each). | en_US |
dc.contributor.affiliationother | McGill University Health Centre and McGill University, Montreal, Quebec, Canada ; Dr. MÉnard has received unrestricted educational and research grants as well as consulting and speaking fees from Abbott, Amgen, Inova, Merck, Pfizer, Roche, Schering-Plough, UCB, and Wyeth (less than $10,000 each) and investigator-initiated research grants from Bristol-Myers Squibb, EuroImmun AG, and Roche (more than $10,000 each); he owns stock or stock options in Merck; and he has a license agreement with EuroImmun AG for an anti-Sa enzyme-linked immunosorbent assay. | en_US |
dc.contributor.affiliationother | University of Pittsburgh, Pittsburgh, Pennsylvania ; Dr. Moreland has received consulting fees, speaking fees, and/or honoraria from Biogen Idec, Centocor, Pfizer, Takeda, KaloBios, ChemoCentryx, UCB, Genentech, Incyte, and Eli Lilly (less than $10,000 each). | en_US |
dc.contributor.affiliationother | University of North Carolina, Chapel Hill | en_US |
dc.contributor.affiliationother | New York University Hospital for Joint Diseases, New York, New York ; Dr. Pincus has received consulting fees, speaking fees, and/or honoraria from Amgen, Abbott, Bristol-Myers Squibb, Centocor, UCB, Wyeth, and Genentech (less than $10,000 each) and investigator-initiated research grants from Amgen, Bristol-Myers Squibb, UCB, and Centocor. | en_US |
dc.contributor.affiliationother | Seattle Children's Hospital, Seattle, Washington | en_US |
dc.contributor.affiliationother | Medical University of Vienna, Vienna, Austria | en_US |
dc.contributor.affiliationother | Institute of Rheumatology, Warsaw, Poland ; Dr. Stanislawska-Biernat has received speaking fees from Abbott and Pfizer (less than $10,000 each). | en_US |
dc.contributor.affiliationother | University of Manchester, Manchester, UK | en_US |
dc.contributor.affiliationother | Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands | en_US |
dc.contributor.affiliationother | UMassMemorial Medical Center and University of Massachusetts Medical School, Worcester | en_US |
dc.contributor.affiliationother | Institute of Rheumatology, Prague, Czech Republic ; Dr. VencovskÝ has received speaking fees from Pfizer, UCB, Abbott, Roche, and Merck, Sharpe, and Dohme (less than $10,000 each). | en_US |
dc.contributor.affiliationother | National Data Bank for Rheumatic Diseases and University of Kansas, Wichita | en_US |
dc.contributor.affiliationother | Women's College Hospital and University of Toronto, Toronto, Ontario, Canada ; Department of Medicine, Women's College Hospital, 76 Grenville Street, 8th Floor, Room 815, Toronto, Ontario M5S 1B2, Canada | en_US |
dc.identifier.pmid | 20872596 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78048/1/27580_ftp.pdf | |
dc.identifier.doi | 10.1002/art.27580 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.